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Abstract 
The APOBEC mutational signature has only recently been detected in a multitude of cancers 
through next-generation sequencing. In contrast, APOBEC has been a focus of virology 
research for over a decade. Many lessons learnt regarding APOBEC within virology are likely 
to be applicable to cancer. In this review, we explore the parallels between the role of 
APOBEC enzymes in HIV and cancer evolution. We discuss data supporting the role of 
APOBEC mutagenesis in creating HIV genome heterogeneity, drug resistance, and immune 
escape variants. We hypothesize similar functions of APOBEC will also hold true in cancer.  
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Key message 
APOBEC mutagenesis creates diversity within viral and tumour cell populations. Sublethal 
APOBEC mutagenesis underlies the formation of HIV drug resistant and immune escape 
variants, and similar functions for APOBEC in cancer are expected. Literature suggests 
APOBEC inhibition is a double-edged sword, because incomplete inhibition may promote 
escape whereas, complete APOBEC inhibition may be attractive as adjuvant therapy. 
 
Introduction 
Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3 (APOBEC3; A3) is the 
name of a seven-membered family of single-stranded DNA cytosine deaminases in humans. 
Independent approaches including analyses of next-generation sequencing data implicated 
APOBEC-catalyzed DNA damage and mutagenesis in breast cancer
1,2
. Subsequent studies 
confirmed and extended the involvement of APOBEC in mutating the cancer genome to at 
least sixteen other cancer types
3-5
. APOBEC signature mutations (C-to-T and C-to-G in TCA 
and TCT trinucleotide motifs) are the most prevalent in cancer after those attributable to 
ageing (C-to-T in CG dinucleotide motifs, most likely due to water-mediated deamination of 
methyl-cytosine)
4
. Furthermore, the clinical relevance of APOBEC in cancer is underscored 
by associations with poor patient outcomes and treatment resistance
6,7
, activation of 
oncogenic drivers
8-10
, tumour subclonal diversification
9,11,12
, and increased prevalence in 
metastases in comparison to primary tumours
13
. 
 
Although involvement of APOBEC mutagenesis in cancer has only recently come to light, 
these enzymes have been a focus of virology research for over a decade, beginning with the 
near simultaneous discoveries of APOBEC3G (A3G) as an HIV-1 restriction factor and as a 
DNA cytosine deaminase
14,15
 (reviewed elsewhere
16,17
). We envision that many lessons learnt 
regarding APOBEC within virology will be applicable to oncology. For this reason, we explore 
the parallels between the role of APOBEC in HIV and cancer mutagenesis. We will especially 
focus on how APOBEC mutagenesis can promote intratumour heterogeneity, drug 
resistance, and immune escape. 
 
The AID/APOBEC superfamily: a diverse set of cytosine deaminase enzymes implicated in 
cancer 
APOBEC3 belongs to the AID/APOBEC superfamily, consisting of: activation induced 
deaminase (AID), APOBEC1 (A1), APOBEC2 (A2), APOBEC3A-H (A3A, A3B, A3C, A3D, A3F, 
A3G, and A3H) and APOBEC4 (A4). AID deaminates cytosines at the immunoglobulin locus, 
enabling antibody gene diversification via somatic hypermutation and class switch 
recombination
18
. A1 was identified originally as a RNA editing enzyme, deaminating 
apolipoprotein B mRNA at a specific position to create an early stop codon
19
, but it also has 
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robust DNA deamination activity
14,20
. The functions of A2 and A4 are still unclear and these 
proteins have yet to show enzymatic activity.  
 
In general, the A3 family members are considered part of the innate immune system, 
forming overlapping barriers to virus and transposon replication. Consistent with such a 
physiological function, A3 genes show profound copy number and amino acid variation in 
mammals. For instance, most humans have 7 A3 genes arranged in tandem, whereas 
rodents have only one at the same genomic location
21,22
, and each A3 gene in humans as 
well as several other mammals manifests high levels of amino acid variation due to positive 
selection
23
.  
 
A3G has been studied intensely in the field of virology, as it was recognized early on to 
deaminate cytosines in cDNA reverse transcription intermediates of retroviruses including 
HIV-1
24,25
. Reverse transcriptase places an adenine opposite to the newly created uracil 
nucleobase, introducing a viral genomic strand GA mutation
26
. This inhibits HIV replication 
by directly rendering the viral genome dysfunctional or by indirectly triggering viral cDNA 
degradation by subsequent uracil DNA glycosylase activity and endonuclease digestion
26,27
. 
A3G can also directly bind to HIV-1 genomic RNA and interfere with viral cDNA synthesis
28
. 
A3D, A3F, and A3H also contribute to HIV-1 mutagenesis through similar mechanisms, and it 
is generally accepted that different subsets of A3 family members restrict the replication of 
different classes of viruses and transposons (reviewed elsewhere
16,17
). 
 
Adding to the complexity of 7 A3 family members in humans, different subsets of A3 
enzymes are expressed in different tissue types
29,30
. Together with high levels of DNA 
sequence similarity (near perfect identity in many regions), determining which of these 
enzymes is responsible for mutagenesis of different cancer genomes has been challenging. 
Thus far, the greatest numbers of publications support A3B and A3A (reviewed more 
extensively elsewhere
31-33
). However, recent reports indicate A3H is also important and, 
together with A3B, may account for the entire APOBEC mutation signature observed in 
breast and lung cancers
34,35
.  
 
APOBEC mutagenesis increases subclonal diversity 
APOBEC mutagenesis occurs independently within single cancer cells and viruses, often 
resulting in strand-coordinated hypermutations (sometimes referred to as kataegis
1
). 
Evidence for A3B upregulation has been found in over half of all cancers
3
 (reviewed 
elsewhere
31
). Additionally, our groups and others have identified APOBEC activity as 
contributing to branched evolution and the acquisition of subclonal mutations later in the 
evolutionary course of lung adenocarcinoma, estrogen receptor (ER)-negative breast cancer, 
head and neck squamous cell carcinoma, and esophageal adenocarcinomas
11,35,36
. A recent 
analysis of the intratumour heterogeneity present in 100 TRACERx patients with untreated 
surgically resected primary non-small cell lung cancer (NSCLC) revealed a significant 
correlation between frequencies of APOBEC signature mutation and the overall number of 
subclonal mutations
9
. Furthermore, in 19 patients, subclonal driver events were detected as 
occurring in the APOBEC mutational context
9
 (Fig. 1a). Moreover, tumours with the largest 
number of subclonal mutations had extensive evidence of APOBEC mutational signatures, 
suggesting that APOBEC activity is a strong mutagenic force late in cancer evolution (Fig. 1b-
c). Subclonal mutations generated from APOBEC activity could potentially drive cancer 
evolution by enabling the acquisition of late driver mutations. Across multiple types of 
cancer, there is evidence that APOBEC mutagenesis is responsible for creating driver 
mutations
5,8,9,12,31
. The most striking examples are 2 helical domain hot spot mutations in 
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PIK3CA in papillomavirus-positive head and neck squamous cell carcinomas (E542K and 
E545K)
8
.  
 
APOBEC expression has also been reported to impact responses to cancer therapy. In ER-
positive breast cancer, A3B mRNA expression levels inversely correlated with clinical benefit 
to tamoxifen, and A3B overexpression correlated with tamoxifen resistance in mouse 
xenograft models, implicating the enzyme in promoting drug resistance
6
. Similarly, an 
enrichment of A3B mutations was observed in chemotherapy-resistant urothelial 
carcinomas
37
.  
 
APOBEC-induced mutagenesis is also prevalent in HIV-1 proviral DNA sequences
38
, with 
some reports estimating the percentage of new mutations attributable to APOBEC activity to 
be as high as 98%
39
. However, other studies have estimated lower contributions for APOBEC 
in HIV-1 genetic variation, and definitive work has yet to be done to dissociate the 
contributions of APOBEC from mistakes made by the non-proofreading viral reverse 
transcriptase
38,40
. Nevertheless, APOBEC activity has been linked to early diversification in 
newly infected individuals as the transmitted founder virus adapts in response to the 
immune pressure exerted within its new host
41
. Thus, APOBEC mutagenesis has the 
capability to increase subclonal diversity in both cancer and HIV, with the potential for a 
profound impact on the subsequent evolution of both the tumour and the virus (2).  
The fact that APOBEC increases diversity is likely to be important for the clinical course of 
both diseases, since genetic heterogeneity is a substrate for Darwinian evolution and is likely 
to confound treatments. Indeed, in some cancers, increased intratumour heterogeneity has 
been shown to correlate with a shorter progression free survival
42,43
. Additionally, measures 
of genetic heterogeneity have been associated with poor progression free survival in 
cancer
44
 and intermediate thresholds of copy number instability correlate with poorest 
clinical outcomes
31
, as they presumably allow for diversity without exceeding toxic levels of 
genomic instability (Fig. 2). Paralleling findings in cancer, among patients with HIV exhibiting 
rapid disease progression, there are fewer hypermutated viral sequences as well as fewer 
minimally edited sequences, suggesting that suboptimal APOBEC activity may enhance 
genetic diversity, allowing an increase in pathogenicity
39
 (Fig. 2). From a clinical standpoint, 
this suggests that successful and complete inhibition of APOBEC enzymatic activity may 
provide a way to limit subclone diversification and potentially enable normal adaptive 
immune responses to control or clear HIV-1 infection
45
. Conceivably, complete inhibition of 
APOBEC enzymatic activity may limit tumour evolution and boost the efficacy of a variety of 
targeted or immune therapies that often fail due to the acquisition of escape variants 
brought about by resistance mutations and/or subclonal neoantigens.  
 
Additional lessons from HIV: APOBEC mutagenesis fuels drug resistance and immune 
escape 
In order for HIV and cancer to replicate effectively in human hosts, these pathogenic entities 
must constantly avoid detection and destruction by innate and adaptive immune responses. 
As a consequence of this predator-prey relationship, lentiviruses and cancer have evolved 
elegant mechanisms to avoid or actively counteract immune responses. One of these 
overlapping mechanisms between HIV and cancer appears to entail co-opting APOBEC 
mutagenesis as a means of immune evasion. 
 
Lentiviruses and host A3 genes have co-evolved for millions of years in non-human primate 
relatives
46
 and more recently in humans
47
. HIV-1, as well as other lentiviruses, has adapted 
to suppress A3-mediated innate anti-viral activity through utilizing the viral infectivity factor 
(Vif) as a defensive measure
15,25
. Vif counteracts A3 functionality by polyubiquitination and 
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proteasomal degradation
48
. Additionally, Vif has been shown to affect A3G translation 
through mRNA binding
49
 and A3G gene transcription through heterodimerization with the 
transcription co-factor CBF-β50. These discoveries indicate that targeting the Vif-APOBEC3 
interaction may be a novel avenue to combat HIV infection. However, over a decade of 
virology research into the A3-mediated restriction mechanism has demonstrated that 
interventions in this pathway may be a double-edged sword. Several studies have found that 
the range of APOBEC mutagenesis within HIV virions can vary largely. Lethal HIV 
mutagenesis will be selected against in vivo, and moderate APOBEC mutagenesis appears to 
induce sublethal variation that fuels viral heterogeneity and immune escape
41,51-53
 (Fig. 3). 
Similar to cancer
54
, viral genetic heterogeneity together with an appropriate selective 
pressure can enable the emergence of resistant populations. Sublethal GA mutations in 
the DNA sequence motif preferred by A3G have been observed in drug-resistant HIV 
variants
55-58
 and immune escape variants
38,41,51,53
 (Fig. 2). Mutations in the APOBEC motif are 
enriched in cytotoxic T lymphocyte (CTL) epitopes of HIV, and can result in diminished CD8+ 
T cell responses against previously antigenic epitopes, suggestive of selection as a 
consequence of immune escape
38
 (Fig. 4). Finally, within cancer there is early evidence that 
APOBEC correlates with the overexpression of the immune checkpoint molecule PD-L1, 
potentially contributing to the development of immune exhaustion
59
 (Fig. 4). Indeed, early 
clinical trial data suggest that reversing immune exhaustion with an anti-PD-L1 antibody 
enhances the immune response against HIV in a subset of participants
60
. 
 
Some of the evolutionary dynamics that have been identified in HIV in response to therapy 
resistance also appear to apply to cancer. For example, in HIV-1, the V3 loop of gp120 
interacts with the host cellular coreceptor CCR5 in order to gain entry to the cell. CCR5 
antagonists bind CCR5 and prevent the entry of CCR5-tropic HIV-1
61
. A common route of 
CCR5 antagonist resistance is the emergence of HIV-1 variants using CXCR4 instead of CCR5 
as a coreceptor for cellular entry 
62,63
. Independent studies detected minor CCR5 antagonist-
resistant variants containing resistance mutations in the APOBEC context at baseline that 
were rapidly selected through therapeutic selective pressure
55,56
. Complementary to these in 
vivo studies, in vitro experiments point towards APOBEC mutagenesis generating subclonal 
resistance mutations which are under positive selection during drug exposure
58
. Similarly, in 
cancer, minor drug resistant variants are rapidly selected upon treatment (reviewed in 
Schmitt et al.
64
), although the contribution of APOBEC in this process remains to be 
quantified.  
 
An optimal range of APOBEC mutagenesis may exist for both HIV and tumour evolution (Fig. 
2). It has been shown that several Vif mutants are less potent in inhibiting A3G, with Vif-
K22H incapable of fully neutralizing A3G and therefore appearing to enable sufficient levels 
of sublethal A3G mutagenesis for the emergence of antiretroviral resistance
57
. Thus, it 
appears that suboptimal A3G mutagenesis is less effective in inactivating the viral genome 
and in contrast may promote drug resistance and immune escape
38,45,58
. There are also 
parallels in the context of APOBEC mutagenesis of the cellular genome. Extensive A3B and 
A3A mutagenesis induces a DNA damage response (DDR) and at excessive levels it is toxic to 
the cell
2,65-69
. Therefore, similar to HIV, cancer cells may have to attenuate APOBEC 
mutagenesis, enhance repair mechanisms, and/or or dampen the DDR pathways to help 
ensure optimal cell survival (Fig. 2). For instance, loss of p53 enables DNA damage tolerance 
to A3B-mediated mutagenesis
65
 and correlates positively with A3B overexpression in breast 
cancer
2
. Furthermore, a recent report focusing on Y-family polymerases and PrimPol, a 
translesion synthesis (TLS) polymerase with re-priming properties, found that PrimPol as 
well as POLK and POLI may serve to limit the detrimental effects of APOBEC mutagenesis
70
. 
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In addition to sublethal APOBEC mutagenesis driving tumour heterogeneity, APOBEC has 
recently also been shown to produce replication stress in cancer
65,71,72
. This complements 
our previous observation that replication stress itself can drive A3B expression and activity
73
, 
which suggests a positive feedforward loop involving replication stress and APOBEC 
mutagenesis (Fig. 5). We have previously implicated replication stress in inducing a 
widespread endogenous DNA damage response as a biological barrier to tumour 
progression
74-76
, as well as driving chromosome segregation errors and ensuing 
chromosomal instability (CIN)
76,77
. It is therefore conceivable that oncogene-induced and 
APOBEC-induced replication stress itself is a driver of CIN in cancer. Furthermore, APOBEC 
may provide a cancer cell the necessary genomic plasticity to evade immune surveillance. 
Firstly, a large subclonal neoantigen burden has been associated with a poor response to 
immunotherapy
78
 and conceivably APOBEC-induced subclonal neoantigens may contribute 
to this process. Although the mechanism of how subclonal neoantigens potentially confound 
the response to immunotherapy is still unclear, it is conceivable that subclonal neoantigens 
foster the outgrowth of T cells that are reactive towards subclonal neoantigens that 
outcompete T cells reactive towards clonal neoantigens. This may result in the outgrowth of 
T cells that are only reactive to a proportion of the tumour population, diminishing chances 
of total tumour control. Secondly, ongoing chromosome missegregations (i.e. CIN) may 
enable the dynamic loss of immunogenic clonal neoantigens
79
. In effect, CIN-mediated loss 
of clonal neoantigens (provided these mutations are not required for tumour fitness) as well 
as the acquisition of subclonal neoantigens (due to APOBEC activity) could both aid immune 
evasion. Interestingly, highly aneuploid (i.e. an abnormal state of chromosomal copy 
number) tumours have less immune infiltration and are associated with a worse patient 
survival than less aneuploid tumours
80,81
. It is yet to be quantified to which extent APOBEC-
induced replication stress and potential ensuing CIN contributes to the process of immune 
evasion.  
 
Therapeutic considerations 
By analogy to hypermutation and hypomutation within HIV
45
, there are at least 2 general 
strategies for targeting APOBEC in cancer. The first strategy is therapy by hypermutation, by 
enhancing the mutagenic effects of APOBEC to the point where cancer cells suffer 
catastrophic levels of DNA damage and selectively die. Indeed, recent studies have 
suggested that DNA damage response inhibitors, such as PARP and ATR inhibitors, may 
sensitize tumour cells with high levels of APOBEC to an APOBEC-dependent death
65,71,72
.  
 
The second strategy is therapy by hypomutation, by inhibiting APOBEC-dependent tumour 
evolution and potentially suppressing adverse outcomes including recurrence, metastasis, 
and drug resistance. Constraining cancer evolvability may be accomplished with drugs to 
inhibit APOBEC gene expression
73,82
 or with chemical inhibitors of DNA deaminase activity 
(for exemplary studies on A3G see
83-85
). Proof of principle has been achieved with a genetic 
knockdown of A3B causing an improvement in the durability of tamoxifen treatment of ER+ 
xenograft tumours in mice
6
.  
 
Besides harnessing APOBEC through a cancer cell intrinsic mechanism, a complementary 
strategy may be provoking immune responses to cancer cells with high levels of APOBEC-
induced neoantigens. It is important to consider whether neoantigens are present in the 
trunk of the tumour (clonal) or in the branches (subclonal), since clonal neoantigens may 
improve response to immune checkpoint blockade in contrast to subclonal neoantigens
78
. 
Interestingly, one APOBEC-mediated mutational signature (signature 2) is primarily found in 
the branches of multiple different cancer types
12
. In contrast, the other APOBEC-mediated 
mutational signature (signature 13) is primarily found in the trunk of bladder cancer
12
. This 
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could potentially explain paradoxical effects of APOBEC mutagenesis on immune 
surveillance and patient outcome. For example, in breast cancer, A3B expression is reported 
to worsen overall patient survival
6,7
. In contrast, APOBEC mutagenesis within bladder cancer 
has been correlated with an improved patient outcome
86,87
, although the influence of 
APOBEC on survival in bladder cancer is still a matter of debate
88
. Therefore, it is conceivable 
that patients with tumours containing extensive clonal APOBEC mutagenesis, in contrast to 
subclonal APOBEC mutagenesis, are more suitable for immune checkpoint blockade.  
 
It is also important to note that several APOBEC family members including A3G and A3H are 
highly expressed in immune cells, including tumour infiltrating T cells, and correlated with 
improved outcomes
89,90
. Thus, as studies advance, it will be crucial to not only consider 
APOBEC expression and mutation signature in the tumour itself, but also APOBEC expression 
in the larger tumour microenvironment. Immunohistochemistry approaches would be ideal 
to help address these relationships, but specific monoclonal antibodies for each human 
APOBEC family member have been challenging to develop due to extensive protein 
similarity. 
 
Conclusions 
Despite the numerous studies that have detected APOBEC-associated mutations by 
sequencing clinical cancer samples, it is still not fully clear why APOBEC mutagenesis is such 
a widespread and recurring mutational signature. In this review, we have postulated 
functions of APOBEC in cancer through exploring the past virology research focused on HIV 
and APOBEC. Within the field of virology, sublethal APOBEC mutagenesis of HIV virions has 
been linked to increasing HIV diversity and the creation of drug and immune escape variants. 
Conceivably, similar functions for APOBEC mutagenesis may be operating, and be selected 
for, during cancer evolution with clear opportunities for the development of novel 
therapeutic interventions.  
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Figure legends 
 
Figure 1 APOBEC mutagenesis within the TRACERx 100 cohort. 
(A) Phylogenetic trees of TRACERx patients harbouring a subclonal driver mutation in an 
APOBEC preferred motif are shown. The mutation is indicated near the clone in which it 
occurs. Clonal clusters are shown in blue, subclonal clusters are shown in red, and subclonal 
clusters containing the driver mutation in a preferred APOBEC motif are show in yellow. (B) 
The total numbers of mutations in each patient are shown, with mutations in an APOBEC 
context shown in yellow and all other mutational contexts shown in green. (C) The total 
numbers of driver mutations in each patient are shown, with mutations in an APOBEC 
context shown in yellow and all other mutational contexts shown in green. (D) The fraction 
of subclonal mutations for each patient that could be attributed to APOBEC activity are 
shown, with mutations in an APOBEC context shown in yellow and all other mutational 
contexts shown in green. 
 
Figure 2 Parallels between APOBEC mutagenesis in HIV and cancer.  
(A) Within HIV, APOBEC mutagenesis is counteracted through Vif. As APOBEC mutagenesis 
increases, the chance of lethal mutagenesis and population variation increases. The trade-
off between lethal mutagenesis and population variation creates an optimal range in which 
APOBEC mutagenesis increases population fitness. (B) Within cancer, the toxic effects of 
APOBEC mutagenesis is counteracted through DNA damage repair and DNA damage 
tolerance. As APOBEC mutagenesis increases, the chance of lethal mutagenesis and 
population variation increases. The trade-off between lethal mutagenesis and population 
variation creates an optimal range in which APOBEC mutagenesis increases population 
fitness. 
 
Figure 3 Potential roles of APOBEC supporting the escape and progression of HIV and 
cancer. (A) Sublethal APOBEC mutagenesis promotes the formation of drug escape and 
immune escape variants in HIV that will be selected upon exposure to treatment or the 
immune system. (B) Sublethal APOBEC mutagenesis promotes the formation of drug escape 
and immune escape variants in cancer that will be selected upon exposure to treatment or 
the immune system. APOBEC mutagenesis also underlies the formation of driver gene 
mutations and potentially also replication stress-induced genomic instability, although the 
latter is speculative. 
 
Figure 4 APOBEC mutagenesis promotes HIV immune escape and potentially also that of 
cancer. APOBEC mutations have been identified in CTL epitopes of HIV. APOBEC 
hypermutation has been linked to PD-L1 ligand overexpression and potentially contributes 
to immune exhaustion of tumour infiltrating lymphocytes. Studies within the HIV literature 
are suggestive of sublethal APOBEC mutagenesis driving the expansion of escape variants. 
 
Figure 5 A feedforward replication stress-APOBEC loop potentially drives subclonal 
somatic points mutations and copy number variations. APOBEC induces subclonal somatic 
point mutations and has recently been shown to induce replication stress. APOBEC-
mediated replication stress could potentially contribute to CIN.  
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